texte alternatif                                    

    List of publications of Mattia Rediti


      Peer-reviewed journal articles (17)
  1. 1. Serra, M., Rediti, M., Collet, L., Lifrange, F., Venet, D., Occelli, N., Papagiannis, A., Vincent, D., Rouas, G., Larsimont, D., Vikkula, M., Duhoux, F. P., Rothé, F., & Sotiriou, C. (2026). Spatial transcriptomics reveals tumor microenvironment-driven subtypes of invasive lobular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 123(6), e2517567123. doi:10.1073/pnas.2517567123
  2. 2. Joaquin Garcia, A., Semba, T., Rediti, M., McGrail, D. J., Xie, X., Wang, X., Rampa, D. R., Venet, D., Buisseret, L., Majjaj, S., Kammler, R., Colleoni, M. A., Loi, S., Viale, G., Regan, M. M., Rothé, F., Sotiriou, C., & Ueno, N. T. (2025). Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00. iScience, 28(8), 112964. doi:10.1016/j.isci.2025.112964
  3. 3. Rediti, M., Fimereli, D., Mileva, M., Wimana, Z., Venet, D., Flamen, P., Guiot, T., de Vries, E. E., Schröder, C. P., Menke-van der Houven van Oordt, W. C., Maetens, M. M., Majjaj, S., Larsimont, D., Rothé, F., Sotiriou, C., & Gebhart, G. (2025). Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial. Clinical cancer research, 31(1), 110-121. doi:10.1158/1078-0432.CCR-24-1007
  4. 4. Rediti, M., Venet, D., Joaquin Garcia, A., Maetens, M. M., Vincent, D., Majjaj, S., El-abed, S., Di Cosimo, S., Ueno, T., Izquierdo, M., Piccart-Gebhart, M., Pusztai, L., Loi, S., Salgado, R., Viale, G., Rothé, F., & Sotiriou, C. (2024). Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nature communications, 15(1), 10402. doi:10.1038/s41467-024-54621-3
  5. 5. Fernandez-Martinez, A., Tanioka, M., Ahn, S.-G., Zagami, P., Pascual, T., Rediti, M., Tang, G., Hoadley, K. A., Venet, D., Rashid, N. U., Spears, P. A., Di Cosimo, S., de Azambuja, E., Choudhury, A., Rastogi, P., Islam, M. N., Cortes, J., Llombart-Cussac, A., Swain, S. M., Sotiriou, C., Prat, A., Perou, C. M., & Carey, L. A. (2024). Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC). Annals of oncology. doi:10.1016/j.annonc.2024.12.010
  6. 6. Wang, X., Venet, D., Lifrange, F., Larsimont, D., Rediti, M., Stenbeck, L., Dupont, F., Rouas, G., Garcia, A. J., Craciun, L., Buisseret, L., Ignatiadis, M., Carausu, M., Bhalla, N., Masarapu, Y., Villacampa, E. G., Franzén, L., Saarenpää, S., Kvastad, L., Thrane, K., Lundeberg, J., Rothé, F., & Sotiriou, C. (2024). Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nature communications, 15(1), 10232. doi:10.1038/s41467-024-54145-w
  7. 7. Fernandez-Martinez, A., Rediti, M., Tang, G., Pascual, T., Hoadley, K. K., Venet, D., Rashid, N. N., Spears, P. P., Islam, M. N., El-abed, S., Bliss, J. M., Lambertini, M. M. P. M., Di Cosimo, S., Huobe, J., Goerlitz, D., Hu, R., Lucas, P. P., Swain, S. S., Sotiriou, C., Perou, C. C., & Carey, L. L. (2024). Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2 -Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. JAMA oncology. doi:10.1001/jamaoncol.2023.7304
  8. 8. Rediti, M., Fernandez-Martinez, A., Venet, D., Rothé, F., Hoadley, K. A., Parker, J. S., Singh, B., Campbell, J. D., Ballman, K. V., Hillman, D. W., Winer, E. P., El-Abed, S., Piccart, M., Di Cosimo, S., Symmans, W. F., Krop, I., Salgado, R., Loi, S., Pusztai, L., Perou, C. M., Carey, L. A., & Sotiriou, C. (2023). Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature communications, 14(1), 7053. doi:10.1038/s41467-023-42635-2
  9. 9. Joaquin Garcia, A., Rediti, M., Venet, D., Majjaj, S., Kammler, R., Munzone, E., Gianni, L., Thürlimann, B., Láng, I., Colleoni, M. A., Loi, S., Viale, G., Regan, M. M., Buisseret, L., Rothé, F., & Sotiriou, C. (2023). Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00. Clinical cancer research. doi:10.1158/1078-0432.CCR-23-1267
  10. 10. Wang, X.-M., Collet, L., Rediti, M., Debien, V., De Caluwé, A., Venet, D., Romano, E., Rothé, F., Sotiriou, C., & Buisseret, L. (2023). Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. Journal of Clinical Medicine, 12(3). doi:10.3390/jcm12030953
  11. 11. Fimereli, D., Venet, D., Rediti, M., Boeckx, B., Maetens, M., Majjaj, S., Rouas, G., Marchio, C., Bertucci, F., Mariani, O., Capra, M., Bonizzi, G., Contaldo, F., Galant, C., Van den Eynden, G., Salgado, R., Biganzoli, E., Vincent-Salomon, A., Pruneri, G., Larsimont, D., Lambrechts, D., Desmedt, C., Brown, D. N., Rothé, F., & Sotiriou, C. (2022). Timing evolution of lobular breast cancer through phylogenetic analysis. EBioMedicine, 82, 104169. doi:10.1016/j.ebiom.2022.104169
  12. 12. Rothé, F., Venet, D., Peeters, D., Rouas, G., Rediti, M., Smeets, D., Dupont, F., Campbell, P., Lambrechts, D., Dirix, L. Y., Sotiriou, C., & Ignatiadis, M. (2022). Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. NPJ breast cancer, 8(1), 79. doi:10.1038/s41523-022-00445-7
    13. << Previous 1 2 Next >>